Related Experiment Video
Updated: Sep 19, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
m6A reader IGF2BP2-stabilized lncRNA LHX1-DT inhibits renal cell carcinoma (RCC) cell proliferation and invasion by
Chunming Zhu1, Ruiming Li2, Xiangyun You2,3,4
1Department of Family Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Abstract:
N6-methyladenosine (m6A) has been established as a critical regulator in various human cancers. However, the role of m6A modification in renal cell carcinoma (RCC) and its interaction with long non-coding RNA LHX1-DT (LHX1-DT) remains unclear. Differentially expressed lncRNAs and m6A levels were identified through microarray analysis. The interaction between IGF2BP2 and LHX1-DT was examined via RNA immunoprecipitation and luciferase reporter assays. LHX1-DT expression was found to be downregulated in RCC tissues, and reduced expression of LHX1-DT was associated with poor overall survival in RCC patients. Functional assays demonstrated that overexpression of LHX1-DT significantly inhibited RCC cell proliferation and invasion. The m6A reader protein IGF2BP2, mediated by METTL14, recognized the m6A modification site on LHX1-DT and promoted its stability. Additionally, LHX1-DT acted as a competing endogenous RNA (ceRNA) by sponging miR-590-5p, which in turn downregulated PDCD4, thereby inhibiting RCC cell proliferation and invasion. LHX1-DT serves as an independent prognostic biomarker for RCC, and the IGF2BP2/LHX1-DT/miR-590-5p/PDCD4 axis represents a novel therapeutic target for RCC progression.
Insights
N6-methyladenosine (m6A) modification regulates renal cell carcinoma (RCC). Long non-coding RNA LHX1-DT, stabilized by IGF2BP2, inhibits RCC progression and serves as a prognostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- N6-methyladenosine (m6A) is a critical regulator in human cancers.
- The role of m6A modification and long non-coding RNA LHX1-DT in renal cell carcinoma (RCC) is not fully understood.
Purpose of the Study:
- To investigate the role of m6A modification and LHX1-DT in RCC.
- To elucidate the interaction between IGF2BP2 and LHX1-DT in RCC progression.
Main Methods:
- Microarray analysis to identify differentially expressed lncRNAs and m6A levels.
- RNA immunoprecipitation and luciferase reporter assays to examine protein-RNA interactions.
- Functional assays (e.g., cell proliferation, invasion) to assess the impact of LHX1-DT.
Main Results:
- LHX1-DT was downregulated in RCC tissues and associated with poor prognosis.
- Overexpression of LHX1-DT inhibited RCC cell proliferation and invasion.
- IGF2BP2 recognized m6A on LHX1-DT, enhancing its stability.
- LHX1-DT sponged miR-590-5p, downregulating PDCD4 and inhibiting RCC progression.
Conclusions:
- LHX1-DT is an independent prognostic biomarker for RCC.
- The IGF2BP2/LHX1-DT/miR-590-5p/PDCD4 axis is a potential therapeutic target for RCC.
Related Concept Videos
MicroRNAs
lncRNA - Long Non-coding RNAs
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

